Bullbearadvisor 
Moderna, Inc. (MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in the development of messenger RNA (mRNA) therapeutics and vaccines, aiming to harness mRNA technology to produce proteins that can prevent or treat diseases. Moderna's product pipeline includes vaccines for infectious diseases, cancer immunotherapies, and treatments for rare diseases. The company gained global recognition for its rapid development of an mRNA-based COVID-19 vaccine during the pandemic. modernatx.com
Over the past 52 weeks, Moderna's stock has traded between $29.25 and $170.47. wsj.com
Analyst recommendations for MRNA include 65% buy ratings from 32 analysts, indicating a generally positive outlook on the stock. chartmill.com
Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!
